Oncogenic activation of phosphatidylinositol-3-kinase (PI3K), AK strain transforming (AKT), and mechanistic/mammalian target of rapamycin (mTOR) pathways are the most frequently activated in cancers, including AML patients (5). The gene discussed is AKT1; the disease is acute myeloid leukemia.